Part No: P207Issued year: 2019File size: 1.25mbFile type: pdf
This poster compares various sample preparation techniques (mixed-mode SPE (EVOLUTE EXPRESS CX, phospholipid depletion (ISOLUTE PLD+), supported liquid extraction (ISOLUTE SLE+) and dual mode extraction (ISOLUTE HYDRO DME+) for extraction of a panel of 98 drugs of abuse from urine.
Part No: P052Issued year: 2013File size: 0.48mbFile type: pdf
Pain management therapy warrants constant monitoring of therapeutic levels of prescribed drug levels in patient urine samples. The number of samples being submitted for analysis has increased dramatically in the last 10 years with improvements in high throughput automated screening capabilities. Patient samples analysis is complicated by the need for an effective sample preparation methodology that can extract target analytes from complex matrices with good efficiency. Further complicating the process is the need to enzymatically hydrolyse the glucoronidated metabolites prior to extraction from the urine matrix. A fully automated sample preparation process using a TECAN Freedom EVO® 100 was designed to incorporate both the enzymatic hydrolysis and subsequent sample preparation assay as one continuous workflow. Supported Liquid Extraction (ISOLUTE SLE+) which offers an efficient alternative to traditional liquid-liquid extraction (LLE) and solid phase extraction (SPE) techniques was used to extract a suite of pain management drugs from spiked urine samples. A recovery and quantitation assay was run on the TECAN Freedom EVO® 100 using mock patient samples to demonstrate utility of automation process.
MSACL, Pain Management, Biotage, SPE, SLE, LLE, Supported Liquid Extraction, Drugs, MSACL, San Diego, 2013
Part No: P144Issued year: 2016File size: 0.6mbFile type: pdf
The ability to extract a broad range of different drugs from a biological matrix allows for the expedited analysis of a patient sample using LC-MS/MS. Typically small molecules are extracted from matrices like urine based on their polarities. A fast and reliable sample preparation method that could be implemented to extract drugs of different polarities from urine could be used as a screening tool to quickly identify the presence of illicit drugs in patient samples using LC-MS-MS.
This poster demonstrates the utility of supported liquid extraction for the extraction of over 30 different acidic, basic and neutral drugs in urine prior to LC-MS/MS.
Part No: P044Issued year: 2012File size: 0.89mbFile type: pdf
The objective was to develop a GC-MS assay for the determination of free benzodiazepines using Supported Liquid Extraction (SLE). The SLE extraction mechanism is very efficient, delivering higher analyte recoveries and cleaner extracts than equivalent LLE methods.
ISOLUTE, SLE, SLE+, Supported Liquid Extraction, Benzodiazepines, Forensic, Drugs, DOA, Drugs of Abuse, SOFT,
Part No: P199.V.2Issued year: 2019File size: 0.96mbFile type: pdf
Solid matrix analysis by LC/MS or GC/MS is generally more involved due to the necessity of multiple manual steps to convert the sample into an extractable form. This poster aims to demonstrate workflow advantages for fingernail analysis; multi-sample homogenization, extraction and analysis for a range of drugs of abuse.
Part No: AN886Issued year: 2017File size: 1mbFile type: pdf
This application note describes the extraction of 96 licit and illicit drugs of abuse from urine prior to UPLC-MS/MS analysis using EVOLUTE® HYDRO CX 96-well plates.
EVOLUTE® HYDRO CX plates offer an efficient way to perform hydrolysis in the well of the extraction plate. This method provides high analyte recovery, reduced extraction time due to the elimination of a sample transfer step as well as the elimination of the column conditioning and equilibration steps, and a reduced risk for sample carryover or cross-contamination due to the elimination of the sample transfer step.
Part No: P163Issued year: 2017File size: 0.58mbFile type: pdf
Over the past decade, the need for non-invasive drug screening that that precludes sample adulteration has become attractive. As a result, detection using oral fluid devices for Drugs of Abuse (DOA) has come to the vanguard of the scientific community. The use of Supported Liquid Extraction (ISOLUTE® SLE+) prior to LC/MS or GC/MS can improve sample cleanliness without forfeiting sample detection within a diverse panel of DOAs. Here, we demonstrate the effects of altering elution solvent polarity and pH for sample pretreatment upon the simultaneous recovery of 34 compounds comprised of opioids, benzodiazepines, and stimulants to directly measure the effects of the oral fluid buffer, OraSure™, upon extraction and signal intensity at presumed LOQs.
Part No: P195Issued year: 2019File size: 0.8mbFile type: pdf
This poster shows an extraction protocol for 12 common drugs of abuse (DOA) to be detected in breast milk using mixed-mode polymeric cation exchange solid phase extraction (SPE).
Using the combination of reliable automation (on Biotage Extrahera) and SPE sample preparation techniques, a method was developed demonstrating the precision, accuracy, linearity, and sensitivity necessary for a robust quantitative workflow.
MSACL NA 2019
Part No: PPS443.V.1Issued year: 2019File size: 2.98mbFile type: pdf
Analysis of drug panels in urine samples can be challenging, and the trend towards larger panels including multiple drug classes compounds the issues faced during method development.
This white paper examines a number of aspects of sample preparation, and their impact on the success of subsequent LC-MS/MS analysis of broad urine panels.
Section 1 examines the applicability of various sample preparation techniques: supported liquid extraction, reverse phase SPE and mixed-mode SPE, to the various classes of drugs extracted. In addition, hydrolysis approaches: enzyme type and protocol used (time, temperature), are compared.
Mixed-mode reverse phase/cation exchange SPE is widely used for extraction of basic drug classes from urine, but the inclusion of drugs and metabolites that exhibit ‘non-typical’ functionality within urine panels can be problematic. Section 2 examines the impact of various parameters (interference wash strength, elution solvent composition) on analyte retention, elution and extract cleanliness with particular focus on zwitterionic (gabapentin, pregabalin) and non-ionic (carisoprodol, meprobamate) drugs.
Part No: P171Issued year: 2017File size: 0.69mbFile type: pdf
This poster demonstrates protocols for the determination of a range of drugs of abuse following collection with the NeoSal™ oral fluid device and GC/MS analysis. The drug suites includes amphetamines and synthetic cathinones, barbiturates, benzodiazepines, cocaine, opiates, cannabinoids and synthetic cannabinoids.
SOFT 2017, Boca Raton
Part No: P174Issued year: 2017File size: 1.44mbFile type: pdf
This poster discusses the potential for a single extraction protocol
for various drugs of abuse classes in whole blood prior to UPLC-MS/MS analysis.
SOFT 2017, Boca Raton
also presented at SFTA, Marseille, France, 2018
Part No: P157Issued year: 2017File size: 0.8mbFile type: pdf
This poster demonstrates that a large urine panel, comprised of 43 DOAs, from multiple drug classes, can be simultaneously screened by mixed-mode cation exchange SPE (using EVOLUTE EXPRESS CX 96 well plates) despite their disparate intermolecular traits, by thoughtfully selecting appropriate organic wash and elution conditions that simultaneously enable sample isolation and detection along with minimizing sample matrix effects.
The extraction method is automated using the Biotage® Extrahera™ Automated sample Preparation Platform.
MSACL 2017, Palm Springs
SOFT 2017, Boca Raton
Part No: P112Issued year: 2014File size: 1.4mbFile type: pdf
This poster demonstrates the extraction of a range of drugs of abuse from oral fluid, collected with common collection devices, prior to UPLC-MS/MS analysis. The target analyte list includes benzodiazepines, z drugs, amphetamines, cathinones, opiates, cocaine, buprenorphine, PCP, THC-COOH, fentanyl and ketamine.
Part No: P132Issued year: 2015File size: 1.55mbFile type: pdf
This poster demonstrates the extraction of a range of drugs of abuse from oral fluid collection devices using supported liquid extraction suitable for UPLC-MS/MS analysis. Unlike some sample preparation techniques, SLE allows for the simultaneous extraction of cross-functional analytes in a single extraction protocol without forfeiting extract cleanliness.
The target analyte list includes benzodiazepines, z drugs, amphetamines, cathinones, opiates, cocaine, buprenorphine, PCP, THC-COOH, fentanyl and ketamine.
Part No: P087Issued year: 2014File size: 0.94mbFile type: pdf
This poster describes the extraction of a range of drugs of abuse (including barbiturates, THC and metabolites, benzodiazepines, z drugs, amphetamines,cathinones, opiates, cocaine, buprenorphine, PCP, fentanyl and ketamine) from oral fluid using supported liquid extraction (ISOLUTE SLE+) columns prior to GC-MS and LC-MS/MS analysis.
Part No: P178 rev 2Issued year: 2018File size: 0.78mbFile type: pdf
This poster evaluates the extraction of a range of drugs of abuse from hydrolyzed and nonhydrolyzed urine using a novel flow through scavenging product, ISOLUTE® HYDRO DME+. Matrix component removal in terms of creatinine and urea, salt residue, pigmentation associated with urobillin content and protein removal will be demonstrated.
Part No: P151Issued year: 2016File size: 0.96mbFile type: pdf
This poster compares the performance of manual processing to a novel automated sample preparation system prior to GC/MS or LC-MS/MS analysis in forensic toxicology applications. Emphasis is placed on the potential for 96-well cross contamination and strategies for its elimination.
Part No: P189 rev 1Issued year: 2018File size: 1.05mbFile type: pdf
This poster describes an improved workflow for the analysis of
drugs of abuse from hair. Implementation of bead homogenization along with automated sample preparation allowed for simplified methodology. The direct solvent extraction approach avoids the need for pre-concentration while maintaining desired LOQs with either 200 or
400 μL of hair extract.